IRIS
LAPUCCI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.107
AS - Asia 927
NA - Nord America 888
Continente sconosciuto - Info sul continente non disponibili 188
SA - Sud America 74
AF - Africa 13
OC - Oceania 3
Totale 7.200
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.969
US - Stati Uniti d'America 834
SG - Singapore 351
CN - Cina 231
VN - Vietnam 189
BD - Bangladesh 66
BR - Brasile 48
FR - Francia 44
HK - Hong Kong 27
CA - Canada 26
DE - Germania 19
GB - Regno Unito 13
AR - Argentina 12
IN - India 11
MX - Messico 11
FI - Finlandia 10
NL - Olanda 10
IQ - Iraq 9
PK - Pakistan 9
JP - Giappone 8
CH - Svizzera 7
ES - Italia 6
AZ - Azerbaigian 5
RU - Federazione Russa 5
SA - Arabia Saudita 5
EC - Ecuador 4
JM - Giamaica 4
PH - Filippine 4
UA - Ucraina 4
IE - Irlanda 3
NI - Nicaragua 3
PL - Polonia 3
SV - El Salvador 3
ZA - Sudafrica 3
AU - Australia 2
CL - Cile 2
HR - Croazia 2
ID - Indonesia 2
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
MA - Marocco 2
PY - Paraguay 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
VE - Venezuela 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IS - Islanda 1
KR - Corea 1
MT - Malta 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
YT - Mayotte 1
ZW - Zimbabwe 1
Totale 7.012
Salva come PNG Salva come JPEG
Città #
Genoa 2.565
Genova 1.276
Vado Ligure 614
Rapallo 383
San Jose 212
Singapore 163
Ashburn 141
Ho Chi Minh City 70
Beijing 59
Hanoi 40
Lauterbourg 38
New York 29
Council Bluffs 27
Hong Kong 26
Milan 20
Santa Clara 20
Boardman 17
Los Angeles 17
Buffalo 15
Chicago 14
Frankfurt am Main 14
Rome 13
St Louis 12
Bordighera 10
Haiphong 10
Helsinki 10
Montreal 9
Mexico City 8
Naples 7
Toronto 6
Dallas 5
Miami 5
Ninh Bình 5
Philadelphia 5
Rio de Janeiro 5
Tampa 5
Tokyo 5
Atlanta 4
Baku 4
Biên Hòa 4
Cardiff 4
Jacksonville 4
São Paulo 4
Thái Nguyên 4
Tianjin 4
Trento 4
Zurich 4
Baghdad 3
Changsha 3
City of London 3
Dublin 3
Houston 3
Madrid 3
Managua 3
Orem 3
Riyadh 3
Rochester 3
Rudolfstetten 3
San Salvador 3
Seattle 3
Warsaw 3
Woodbridge 3
Akron 2
Albuquerque 2
Almaty 2
Amman 2
Amsterdam 2
Aurora 2
Bensalem 2
Bologna 2
Boston 2
Brescia 2
Bình Phước 2
Camp Hill 2
Campbell 2
Charlotte 2
Chester 2
Citrus Heights 2
Colonia 2
Columbus 2
Corona 2
Corryton 2
Da Nang 2
Denver 2
Detroit 2
Erbil 2
Federal Way 2
Florence 2
Guangzhou 2
Hamilton 2
Jeddah 2
Johannesburg 2
Karachi 2
Kingston 2
Kyiv 2
La Plata 2
Lincoln 2
Litchfield Park 2
London 2
Lyndhurst 2
Totale 6.041
Salva come PNG Salva come JPEG
Nome #
Different MRI patterns in MS worsening after stopping fingolimod 207
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 206
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies 193
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 189
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 187
"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?" 177
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 162
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 156
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 154
How much do periventricular lesions assist in distinguishing migraine with aura from CIS? 153
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 150
A longitudinal clinical and MRI evaluation of the treatment with erenumab 147
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 147
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 143
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 141
Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma 140
Assessing upper limb function in Multiple Sclerosis by an engineered glove 134
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 132
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 129
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 128
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 128
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 126
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions 126
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 125
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 123
Effects of aging on finger movements in multiple sclerosis 122
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 121
Clinical and radiological correlates of apathy in multiple sclerosis 120
Neuroimaging Findings in Mild Cognitive Impairment 120
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 115
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 114
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 112
ADVANCED SUSCEPTIBILITY AND DIFFUSION WEIGHTED IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS: FROM RESEARCH TO CLINICAL APPLICATIONS 112
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 105
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis 105
Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis 104
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 99
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series 99
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 98
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 98
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 97
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 97
A real-world study of alemtuzumab in a cohort of Italian patients 96
The effect of Cladribine and Fingolimod treatments on retinal atrophy 95
Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T 82
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 81
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 80
Lesion phenotyping based on magnetic susceptibility in pediatric multiple sclerosis 78
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 78
Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics 77
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia 75
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient 75
The role of disconnection in explaining disability in multiple sclerosis 74
Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes 69
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature 69
A real-world study of Alemtuzumab in a cohort of Italian patients 67
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 61
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience 55
Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies 51
Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection 48
Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis 48
The “central vein sign” to differentiate multiple sclerosis frommigraine 45
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis 42
null 41
Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients 27
null 20
E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy 15
Unmasking the invisible: Correlates and impact of cognitive complaints in MS 7
Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort 3
Totale 7.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.730
article - articoli 26.358
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 976
Totale 55.064
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022339 21 4 12 28 21 30 12 72 27 43 19 50
2022/2023480 43 50 10 47 50 68 7 29 66 14 74 22
2023/2024626 24 42 18 76 35 83 122 37 30 18 36 105
2024/20251.714 105 113 72 90 196 153 155 307 97 97 187 142
2025/20262.790 393 72 199 237 342 156 361 146 235 295 145 209
2026/2027226 226 0 0 0 0 0 0 0 0 0 0 0
Totale 7.200